首页> 美国卫生研究院文献>other >Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells
【2h】

Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells

机译:双靶向纳米颗粒可在体内将自杀基因传递给对化疗耐药的卵巢癌细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ovarian cancer is the most lethal gynecologic cancer. Claudin-3 and-4, the receptors for Clostridium Perfringens Enterotoxin (CPE), are overexpressed in over 70% of these tumors. Here we synthesized and characterized poly(lactic-co-glycolic-acid) (PLGA) nanoparticles (NP) modified with the carboxi-terminal binding domain of CPE (c-CPE-NP) for the delivery of suicide gene therapy to chemotherapy-resistant ovarian cancer cells. As a therapeutic payload we generated a plasmid encoding for the Diphteria Toxin subunit-A (DT-A) under the transcriptional control of the p16 promoter, a gene highly differentially expressed in ovarian cancer cells. Flow cytometry and immunofluorescence demonstrated that c-CPE-NPs encapsulating the CMV GFP plasmid (CMV GFP c-CPE-NP) were significantly more efficient than control NP modified with a scrambled peptide (CMV GFP scr-NP) in transfecting primary chemotherapy-resistant ovarian tumor cell lines in vitro (p=0.03). Importantly, c-CPE-NPs encapsulating the p16 DT-A vector (p16 DT-A c-CPE-NP) were significantly more effective than control p16 DT-A scr-NP in inducing ovarian cancer cell death in vitro (% cytotoxicity: mean ± STDV = 32.9 ± 0.15 and 7.45 ± 7.93, respectively, p=0.03). In vivo bio-distribution studies demonstrated efficient transfection of tumor cells within 12 hours after intraperitoneal (IP) injection of CMV GFP c-CPE-NP in mice harboring chemotherapy-resistant ovarian cancer xenografts. Finally, multiple IP injections of p16 DT-A c-CPE-NP resulted in a significant inhibition of tumor growth compared to control NP in chemotherapy-resistant tumor-bearing mice (p=0.041). p16 DT-A c-CPE-NP may represent a novel dual-targeting therapeutic approach for the selective delivery of gene therapy to chemotherapy-resistant ovarian cancer cells.
机译:卵巢癌是最致命的妇科癌症。产气荚膜梭菌肠毒素(CPE)的受体Claudin-3和-4在这些肿瘤的70%​​以上都过表达。在这里,我们合成并表征了用CPE的羧基末端结合结构域(c-CPE-NP)修饰的聚乳酸-乙醇酸(PLGA)纳米颗粒(NP),用于自杀基因治疗对耐药性的传递卵巢癌细胞。作为治疗有效载荷,我们在p16启动子的转录控制下产生了编码白喉毒素亚基A(DT-A)的质粒,该启动子在卵巢癌细胞中高度差异表达。流式细胞仪和免疫荧光分析表明,封装CMV ​​GFP质粒(CMV GFP c-CPE-NP)的c-CPE-NP在转染原发性化疗耐药性方面比用扰乱肽修饰的对照NP(CMV GFP scr-NP)显着更高。体外卵巢肿瘤细胞系(p = 0.03)。重要的是,封装p16 DT-A载体(p16 DT-A c-CPE-NP)的c-CPE-NP在诱导卵巢癌细胞体外死亡方面比对照p16 DT-A scr-NP更有效(细胞毒性%:平均值±STDV = 32.9±0.15和7.45±7.93,p = 0.03)。体内生物分布研究表明,腹膜内(IP)注射CMV GFP c-CPE-NP的小鼠腹腔内(IP)移植后12小时内即可有效转染肿瘤细胞。最终,与化疗药物耐药的小鼠相比,多次IP注射p16 DT-A c-CPE-NP导致肿瘤生长受到显着抑制(p = 0.041)。 p16 DT-A c-CPE-NP可能代表一种新的双重靶向治疗方法,可选择性地将基因治疗传递给对化疗耐药的卵巢癌细胞。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号